Colorectal Cancer Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Plus Therapeutics, Processa Pharmaceuticals, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pha

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Colorectal Cancer pipeline constitutes 195+ key companies continuously working towards developing 200+ Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Colorectal Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.

The Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Colorectal Cancer Pipeline Report: https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Colorectal Cancer treatment therapies with a considerable amount of success over the years.
• Colorectal Cancer companies working in the treatment market are Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others, are developing therapies for the Colorectal Cancer treatment
• Emerging Colorectal Cancer therapies in the different phases of clinical trials are- 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others are expected to have a significant impact on the Colorectal Cancer market in the coming years.
• In January 2024, Bristol Myers Squibb (BMS) recently disclosed encouraging findings from the Phase III CheckMate -8HW study involving Opdivo (nivolumab) and Yervoy (ipilimumab) as an initial treatment choice for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). This open-label, randomized Phase III trial aims to assess the effectiveness of combining Opdivo and Yervoy compared to the chemotherapy selected by the investigator.

Colorectal Cancer Overview
Colorectal cancer, also known as bowel cancer or colon cancer, refers to cancer that develops in the colon or rectm, which are parts of the digestive system. It typically starts as small, noncancerous clumps of cells called polyps that form on the inner lining of the colon or rectm. Over time, some of these polyps can become cancerous.

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:
• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceutic als
• HLX13: Shanghai Henlius Biotech
• Adagrasib: Mirati Therapeutics
• XL092: Exelixis
• EO2040: Enterome
• Etrumadenant: Arcus Biosciences
• LYL845: Lyell Immunopharma
• Geptanolimab: Apollomics
• HDM201: Novartis Pharmaceuticals
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602 Sunshine: Guojian Pharmaceutical
• Trastuzumab deruxtecan: Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc
• SHR-1701: Suzhou Suncadia Biopharmace uticals Co., Ltd.
• Trilaciclib: G1 Therapeutics
• Lumakras (sotorasib): Amgen
• MRTX849: Mirati Therapeutics

Route of Administration
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Colorectal Cancer Pipeline Therapeutics Assessment
• Colorectal Cancer Assessment by Product Type
• Colorectal Cancer By Stage and Product Type
• Colorectal Cancer Assessment by Route of Administration
• Colorectal Cancer By Stage and Route of Administration
• Colorectal Cancer Assessment by Molecule Type
• Colorectal Cancer by Stage and Molecule Type

DelveInsight's Colorectal Cancer Report covers around 200+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the emerging Colorectal Cancer therapies
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Colorectal Cancer Therapeutics Market include:
Key companies developing therapies for Colorectal Cancer are - Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.

Colorectal Cancer Pipeline Analysis:
The Colorectal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
• Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Colorectal Cancer drugs and therapies
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Colorectal Cancer Pipeline Market Drivers
• Emergence of targeted therapies for mCRC treatment, technical Advancement in molecular subtyping of CRC tumors, increase in product development activities are some of the important factors that are fueling the Colorectal Cancer Market.

Colorectal Cancer Pipeline Market Barriers
• However, limitations in understanding secondary resistance, high Cost of Treatment • Challenges related to precision oncology in mCRC management and other factors are creating obstacles in the Colorectal Cancer Market growth.

Scope of Colorectal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Colorectal Cancer Companies: Plus Therapeutics, Processa Pharmaceutic als, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Guojian Pharmaceutical, Daiichi Sankyo, Gritstone Bio, Inc, Suzhou Suncadia Biopharmace uticals Co., Ltd., G1 Therapeutics, Amgen, Mirati Therapeutics, and others
• Key Colorectal Cancer Therapies: 188RNL-BAM, PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR, 255, Evorpacept (ALX148), CPGJ 602 Sunshine, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Colorectal Cancer Report Introduction
2 Colorectal Cancer Executive Summary
3 Colorectal Cancer Overview
4 Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment
5 Colorectal Cancer Pipeline Therapeutics
6 Colorectal Cancer Late Stage Products (Phase II/III)
7 Colorectal Cancer Mid Stage Products (Phase II)
8 Colorectal Cancer Early Stage Products (Phase I)
9 Colorectal Cancer Preclinical Stage Products
10 Colorectal Cancer Therapeutics Assessment
11 Colorectal Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Colorectal Cancer Key Companies
14 Colorectal Cancer Key Products
15 Colorectal Cancer Unmet Needs
16 Colorectal Cancer Market Drivers and Barriers
17 Colorectal Cancer Future Perspectives and Conclusion
18 Colorectal Cancer Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Colorectal Cancer Epidemiology https://www.delveinsight.com/report-store/colorectal-cancer-crc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Colorectal Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.